← Oncology Approval Tracker

FDA DECISION ·

Orserdu

elacestrant · Stemline Therapeutics

FDA approvalNew therapyBreast cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

For postmenopausal women and adult men with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer progressing after at least one endocrine therapy line.

LAMPGEN ANALYSIS

Why it matters

This oral estrogen receptor degrader gave a molecularly defined group another endocrine option after progression.

What research teams should watch

Document the ESR1 result and previous endocrine treatment before determining whether the indication applies.

Related study operations checklist

See the staffing responsibilities, timing, and handoff questions for this study setting.

ESR1-selected advanced or metastatic disease

PRIMARY RECORDS

Sources